ELUTIA INC. (ELUT) SEC Filings, Apr-Jun 2026

ELUTIA INC. director Guido J. Neels received a grant of stock options covering 106,393 shares of Class A common stock. The options have an exercise price of $0.96 per share and expire on June 11, 2036.

The grant was made automatically under the company’s Non-Employee Director Compensation Program. These options vest and become exercisable on the earlier of the day immediately preceding the company’s first annual meeting following the grant date or the first anniversary of the grant date, if he continues serving on the board.

ELUTIA INC. director Brigid Makes reported receiving a stock option grant as part of the company’s Non-Employee Director Compensation Program. The award covers 106,393 shares of Class A common stock at an exercise price of $0.9600 per share and expires on June 11, 2036. The option vests and becomes exercisable on the earlier of the day immediately preceding Elutia’s first annual meeting following the grant date or the first anniversary of the grant date, subject to her continued service on the board. This is a compensation-related grant and not an open-market share purchase.

ELUTIA INC. Chief Scientific Officer Michelle LeRoux Williams reported routine equity compensation activity. On June 10, 2026, 12,500 restricted stock units vested into Class A Common Stock, and 4,269 shares were withheld at $1.04 per share to cover tax obligations. Following these transactions, she directly holds 118,052 Class A shares and 25,000 restricted stock units, from an original grant of 150,000 units awarded on January 31, 2024 with a scheduled vesting through December 10, 2026.

ELUTIA INC. chief financial officer Matthew Ferguson reported routine equity compensation activity involving restricted stock units that vested into Class A common stock. On the vesting date, 12,500 RSUs converted into 12,500 shares of Class A common stock, as each unit represents one share.

The company withheld 4,485 of these shares at an implied price of $1.04 per share to cover tax withholding obligations, which is recorded as a disposition but not an open-market sale. After these transactions, Ferguson directly owned 480,082 shares of Class A common stock and held 25,000 restricted stock units as of the report.

ELUTIA INC. President and CEO C. Randal Mills reported routine equity compensation activity tied to restricted stock units (RSUs). On June 10, 2026, 27,083 RSUs converted into an equal number of Class A common shares, reflecting a scheduled vesting.

To satisfy tax withholding on this vesting, the issuer withheld 9,718 Class A shares at an indicated value of $1.04 per share, a disposition categorized as payment of tax liability rather than an open-market sale. Following these transactions, Mills directly holds 426,771 Class A shares and 216,666 RSUs.

Footnotes explain that these RSUs were part of a 487,500-unit grant made on January 31, 2024. RSUs covering 162,500 shares vest only if the stock trades at or above $6.00, $10.00, $14.00 and $18.00 for twenty consecutive trading days, while 325,000 time-based RSUs vest on a specified schedule through December 10, 2026, subject to Mills’ continued employment.

ELUTIA INC. director and ten percent owner Kevin Rakin, together with affiliated HighCape entities, reported internal share movements rather than market trades in Class A Common Stock. On June 1, a bona fide gift transferred 70,000 shares, leaving 126,120 shares held directly afterward. A separate 50,000-share transaction reflects a distribution by trusts to their beneficiaries without payment of consideration, with 272,419 shares then held indirectly through trusts. An additional 4,706,559 shares are reported as indirectly held through HighCape investment entities. Footnote disclosures state that Mr. Rakin and the HighCape reporting persons may be deemed to beneficially own these indirect holdings but each disclaims beneficial ownership except to the extent of any pecuniary interest.

Elutia Inc. reported first-quarter 2026 net sales of $3.1 million, up modestly from $3.0 million a year earlier, with gross profit improving to $1.8 million from $1.4 million as cost of goods sold declined.

The company posted a net loss of $7.5 million compared with a $3.9 million loss in 2025, mainly reflecting a $1.7 million loss on revaluation of warrant liability and higher research and development spending as it advances NXT-41 and NXT-41x. Cash and cash equivalents were $28.5 million, and operating cash outflow was $7.8 million. Results also reflect discontinued operations gains tied to prior divestitures and sizable contingent liabilities and insurance receivables related to FiberCel and viable bone matrix litigation.

Elutia Inc. reported first quarter 2026 results, combining higher revenue with a wider loss as it invests in its drug-eluting biomatrix platform. Net sales from continuing operations were $3.1 million, slightly above the prior-year period, while net loss widened to $7.5 million from $3.9 million. GAAP gross margin improved to 57.9%, and adjusted gross margin rose to 66.5%, reflecting early benefits from automated manufacturing.

The company highlighted progress on its breast reconstruction pipeline. FDA review of the 510(k) for NXT-41 remains on track for anticipated clearance in the fourth quarter of 2026, with NXT-41x clearance anticipated in the first half of 2027. Elutia is advancing strategic processes for a potential SimpliDerm divestiture and evaluating acquisition interest in its Cardiovascular product line. Cash and escrowed funds totaled $36.5 million as of March 31, 2026, including $8.0 million in escrow related to a prior divestiture that is expected to be released in the fourth quarter of 2026.